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Type 3 innate lymphoid cells engage in a positive-feedback loop with monocytes that promotes clearance of antibioticresistant Klebsiella pneumoniae pulmonary infections.
INTRODUCTION
Klebsiella pneumoniae is a Gram-negative bacterium that normally resides in the lower gastrointestinal tract. In patients with compromised immune defenses or impaired pulmonary clearance mechanisms, K. pneumoniae can cause severe infections of the lower respiratory tract. The emergence of high-level antibiotic resistance in some strains of K. pneumoniae limits treatment options and, in some cases, renders infections untreatable with available antibiotics. In the absence of effective antibiotics, optimizing or enhancing host immune defenses against K. pneumoniae represents a potential therapeutic option that might improve clinical outcomes.
As a bacterial species, Klebsiella pneumoniae is diverse and composed of a wide array of strains that differ in capsule composition, antibiotic resistance, mucoid phenotype, and virulence. Extensive studies with the rodent-adapted, antibiotic-sensitive strain 43816 of K. pneumoniae have demonstrated that TNF, neutrophils, IL17A, MyD88, and C-type lectins contribute to bacterial clearance from the mouse lung (Cai et al., 2009; Laichalk et al., 1996; Moore et al., 2005; Sharma et al., 2014; Steichen et al., 2013; Ye et al., 2001) . However, which cell types produce defense-associated cytokines and which mediate bacterial clearance is incompletely defined. Further complicating the picture is the recent discovery that antibiotic-resistant strains of K. pneumoniae isolated from patients differ in their dependence on neutrophils or inflammatory monocytes for pulmonary clearance from infected mice . While the clearance of five distinct strains of K. pneumoniae was consistently dependent on inflammatory monocytes, the contribution of neutrophils to clearance was more variable.
Inflammatory monocytes (IMs) are bone marrow-residing leukocytes that, in the setting of infection, rapidly traffic into the bloodstream and circulate to inflamed or infected tissues. IMs are pluripotent and, depending on the inflammatory environment they infiltrate, can acquire phenotypes that extend from pro-inflammatory TNF and iNOS production to immunosuppressive IL10-production (Biswas and Mantovani, 2010; Gordon and Taylor, 2005; Serbina et al., 2003) . Although IMs enhance clearance of a wide range of pathogens, the exact mechanisms by which they promote microbial clearance remain unclear. Because TNF is essential for defense against intracellular pathogens, such as Listeria monocytogenes, and IMs can be prodigious producers of TNF, it has seemed likely that activated IMs mediate at least some level of bacterial clearance by producing TNF. However, the mechanism by which TNF enhances bacterial clearance remains largely undefined.
Pulmonary infection of mice with K. pneumoniae was one of the first infectious disease models to demonstrate the importance of IL-17A for host defense against extracellular bacterial infections (Ye et al., 2001 ). Indeed, IL-17A-deficient mice rapidly succumbed to infection with K. pneumoniae strain 43816 and neutrophils were essential for bacterial clearance. While Th17 CD4 T lymphocytes and gd T cells produce IL-17A (Harrington et al., 2005; Ivanov et al., 2009; Liang et al., 2006; Sutton et al., 2009 ), innate lymphocytes, at least in the gut, appear to be responsible for the major IL-17A-mediated antimicrobial effects (Artis and Spits, 2015) . Innate lymphocytes are essential for defense against intestinal infections with Citrobacter rodentium and Clostridium difficile (Abt et al., 2015; Satoh-Takayama et al., 2008; Sonnenberg et al., 2011; Zheng et al., 2008) ; however, their role in defense against pulmonary infection is less clear. In fact, ILC3s in the respiratory system have not been identified until recently (Kim et al., 2014; Van Maele et al., 2014) . Furthermore, whether inflammatory monocytes and IL-17A-producing cells facilitate each other's effecter functions in response to infection is unknown.
To begin to address the roles of IMs and innate lymphocytes in defense against bacterial pulmonary infection, we investigated mice infected with a highly antibiotic-resistant strain of Klebsiella pneumonia that is cleared by neutrophil-independent but monocyte-dependent mechanisms . We demonstrate that IMs, upon recruitment to the infected lung, produce TNF, which increases innate lymphocyte frequencies and IL-17A production. We show that IL-17A promotes monocytemediated uptake and killing of K. pneumoniae. Our experiments demonstrate that rapid recruitment of IMs to the lung markedly enhances innate lymphocyte responses and that innate lymphocytes engage in crosstalk with IMs by producing IL-17A to enhance bacterial killing.
RESULTS

Inflammatory Monocytes Provide Defense against
Klebsiella pneumoniae Neutrophils and monocytes are rapidly recruited to sites of bacterial infection. To determine the kinetics of inflammatory cell recruitment to the lungs, we inoculated mice intratracheally See also Figure S1 .
with a sublethal dose of K. pneumoniae and quantified inflammatory monocytes (Ly6C hi ) and neutrophils (Ly6G + ) by flow cytometry. Both cell populations increased in frequency within 3 hr of inoculation, with cell numbers peaking at 24 hr and then decreasing ( Figure 1A ). To determine the contribution of neutrophils and monocytes to bacterial clearance from the lungs, we depleted both populations with the anti-Gr1 RB6-8C5 monoclonal antibody (aGr1) or depleted only neutrophils by administering the Ly6G-specific 1A8 monoclonal antibody (aLy6G) or only CCR2 + monocytes by administering diphtheria toxin (DT) to CCR2-DTR mice. Monocyte depletion in K. pneumoniae-infected mice resulted in increased mortality, weight loss, and hypothermia in comparison to undepleted mice ( Figures 1B and 1D ). Confirming our previous results , we found that monocyte depletion resulted in a roughly 10-fold increase in bacterial colony-forming units (CFUs) in the lung, while neutrophil depletion modestly reduced bacterial CFUs ( Figure 1C ). Bacterial dissemination to mediastinal lymph nodes and spleen was also increased in monocytedepleted mice and the rate of bacterial clearance was reduced ( Figure S1A ). Monocyte-depleted CCR2-DTR mice also had higher levels of neutrophil infiltration to the bronchoalveolar lavage fluid (BALF) despite compromised bacterial clearance ( Figure S1B ).
Although predominantly expressed on inflammatory monocytes, CCR2 is also expressed on some NK cells, monocyte/ dendritic cell progenitors, and hematopoietic stem cells. Therefore, in order to determine whether monocytes are mediating protection against K. pneumoniae, we adoptively transferred highly purified CD45.2 + monocytes into monocyte-depleted CD45.1 + CCR2-DTR depleter mice 30 min after challenge with K. pneumoniae ( Figure 2A ). IMs were purified from CCR2-GFP mice based on GFP expression and the lack of expression of FLT3, C-kit, NK1.1, CD19, or CD3. This purification approach circumvented the need for antibody staining of surface markers on IMs (such as CCR2, CD11b, and Ly6C), which might interfere with IM trafficking, while eliminating contaminating cell populations and yielded a purity of greater than 99% Ly6C hi IMs ( Figure S2A ). Transferred CD45.2 + monocytes were detected in the lungs of K. pneumoniae-infected recipient mice as CD11c +
CD11b
+ CD103 neg (Figures 2B, 2D, and S2C) , and achieved numbers that approached those seen in equivalently infected wild-type mice ( Figure 2C ). Transferred monocytes isolated from infected lungs had downregulated Ly6C and upregulated MHC class II, CD11b, and CD11c ( Figures 2D and S2D ), while transferred monocytes isolated from spleen or bone marrow remained Ly6C hi ( Figure S2D ). A single transfer of IMs reduced bacterial CFUs in the lungs of infected, monocyte-depleted CCR2-DTR mice ( Figures 2E and S2B ), supporting a role of monocytes in the clearance of K. pneumoniae from the lung.
Activated Monocytes Are the Predominant Producers of TNF TNF is required for optimal clearance of K. pneumoniae from the lung and IMs, at least during some bacterial infections, are major producers of TNF (Laichalk et al., 1996; Serbina et al., 2003 mice or WT and CCR2-DTR mice and treated mice with DT prior to infection. This mixed bone marrow chimera approach demonstrated that depletion of monocytes from TNF À/À /CCR2-DTR mice markedly impaired clearance of K. pneumoniae from the lung, while bacterial clearance following monocyte depletion from WT/CCR2-DTR mice was normal ( Figure S3C ). The cell population responding to TNF via TNFR1 was not depleted by DT treatment in TNFR1 À/À /CCR2-DTR-mixed bone marrow chimeric mice ( Figure S3C ), suggesting that TNF-responsive cells mediating K. pneumoniae clearance do not express CCR2 and thus are not IMs. In our previous work we described that MyD88 signaling was required for egress of inflammatory monocytes from the bone marrow upon challenge with TLR ligands (Shi et al., 2011) . To better understand the role of MyD88 signaling during K. pneumoniae infection model, we infected WT and MyD88 À/À mice with Kp-MH258 and measured clearance from the lung. MyD88 À/À mice had approximately 10-fold more bacteria in the lung than did WT mice, indicating that MyD88 signaling is critical for defense ( Figure S3D ). MyD88 À/À mice had significantly reduced TNF production (Figure S3E) . These results indicate that MyD88-signaling plays an important role in inducing TNF production in response to K. pneumoniae invasion.
TNF Potentiates IL-17A Production by Innate Lymphocytes
Consistent with previous studies demonstrating that IL-17A plays a key role in pulmonary clearance of K. pneumoniae infection, we found that in vivo administration of an IL-17A blocking monoclonal antibody (aIL-17A) increased mortality in K. pneumoniae-infected mice ( Figure 4A ). IL-17A blockade or infection of IL-17A À/À mice resulted in higher CFUs in lungs following K. pneumoniae infection ( Figure 4B ). IL-17A blockade or deficiency did not reduce recruitment of neutrophils to infected lungs ( Figure S4B ), following K. pneumoniae infection, suggesting that the protective effect of IL-17 does not result from enhanced neutrophil recruitment. Because deficiency of monocytes, TNF, or IL-17A similarly increased susceptibility to K. pneumoniae infection, we next investigated IL-17A production in K. pneumoniae-infected TNFR1 À/À and DT-treated CCR2-DTR mice. We found significantly reduced IL-17A production in infected TNFR1 À/À and DT-treated CCR2-DTR mice when compared to infected WT mice, suggesting that TNF signaling and CCR2 + cells are required for optimal IL-17A expression (Figure 4C) . Although IL-17A blockade enhanced infection in WT mice, treatment of TNF À/À or monocyte-depleted CCR2-DTR mice with IL-17A blocking antibody did not worsen K. pneumoniae infection ( Figure 4D ), suggesting that TNF and IL-17A function in series within the same antimicrobial defense pathway. Kinetic analysis of TNF and IL-17A production and monocyte recruitment during the first 3 hr following pulmonary K. pneumoniae infection suggested that monocyte recruitment and TNF production preceded induction of IL-17A production ( Figure 4E ). IL-17A can be produced by Th17 CD4 T cells and by type 3 innate lymphocytes (ILC3). Induction of IL-17A expression during the first 2 days of pulmonary K. pneumoniae infection suggested that ILC3 cells could be the major IL-17A producers. Clearance of K. pneumoniae from lungs was similar in Rag2 À/À and WT mice ( Figure 5A ), but markedly reduced in Rag2/common gamma chain double-knockout (Rag2/cgc À/À ) mice, which lack all ILC subsets ( Figure 5B ). Mortality following K. pneumoniae infection of Rag2/cgc À/À mice was markedly increased when compared to either WT or Rag2 À/À mice ( Figure 5C ). Depletion of ILCs in Rag2 À/À mice with a depleting monoclonal antibody specific for CD90 resulted in markedly increased pulmonary K. pneumoniae CFUs following infection ( Figure 5D ) and enhanced weight loss and mortality ( Figures S5A and S5B ), indicating that ILCs enhance bacterial clearance. Although ILC3 cells can produce IL-17A, they are also known to produce IL-22, a cytokine that contributes to antibacterial defenses. However, IL-22 does not detectably contribute to early defense ance defect in K. pneumoniae-infected Rag2/cgc À/À mice ( Figure 6C ) and reduced mortality ( Figure 6D ). Adoptive transfer of ILCs from Rag2
À/À mice, reduced the bacterial burden in the lungs of recipient Rag2/cgc À/À mice ( Figure S4D ). Since
ILC3s are the only ILC subset that produces IL-17, this result demonstrates that protection is attributable to IL-17-producing ILC3s. To determine whether CCR2 + monocytes and IL-17-producing ILC3 cells contribute to the same bacterial clearance pathway in series, as noted previously for monocytes, TNF, and IL-17 ( Figure 4D ), we generated Rag2/cgc À/À CCR2-DTR mice and challenged them with K. pneumoniae. Figure 6E demonstrates that monocyte depletion in Rag2/cgc À/À CCR2-DTR did not result in increased CFUs compared to Rag2/ cgc À/À mice, suggesting that CCR2 + monocytes and ILC3 cells mediate K. pneumoniae clearance along the same functional axis (Figure 6E) . Depletion of IMs or TNF blockade reduced the recruitment of ILCs to the lung ( Figure 6F ). The increased frequency of ILCs following infection was not the result of increased proliferation as bromodeoxyuridine (BrDU) incorporation was similarly low in ILCs from uninfected and K. pneumoniae-infected mice ( Figure S6B ). Transcription of CCL20, the ligand for CCR6, was reduced in the lungs of IM-depleted or TNF-blocked animals ( Figure 6G ), suggesting that IM-derived TNF enhances CCL20 expression, thereby facilitating recruitment of CCR6 + ILC3s.
A single transfer of purified IMs into K. pneumoniae infected, monocyte-depleted mice increased the frequency of total ILCs and, in particular, the frequency of RORgt + ILC3s, but not GATA3 + ILC2s in the lung, providing further evidence for the role of IMs in the recruitment of ILC3s to the site of infection (Figures 6H and 6I) . Kp-MH258 is carbapenem resistant and requires IMs, but not neutrophils, for clearance . We wanted to examine whether IM-ILC-mediated defense mechanisms and IL-17 enhancement apply to the other clinical strains. To this end, we tested a different K. pneumoniae isolate, Kp-MH1867, which is highly antibiotic resistant but sensitive to carbapenems, and which depends on both IMs and neutrophils for clearance . Both IL-17 deficiency and IM depletion rendered mice more susceptible to Kp-MH1867 ( Figure S5C) , and the IL-17 response to infection was dampened by IM depletion in CCR2-DTR mice ( Figure S5D ). Furthermore, IL-17A + cells in the infected lung were Lineage À CD45 + CD90 + , indicating that they were ILCs ( Figure S5E ), and depletion of ILCs by anti-CD90-depleting antibody led to a higher bacterial burden ( Figure S5F ). These data indicate that inflammatory monocytes and ILCs contribute to defense against carbapenem-resistant and carbapenem-sensitive strains. antibody in order to prevent IL-17RA signaling following adoptive transfer ( Figure S7A ). Clearance of IM-associated bacteria that were transferred into recipient mice was measured after 2 hr, and it revealed increased survival and expansion of IM-associated K. pneumoniae in the absence compared to the presence of IL-17A ( Figure 7C ). Short-term IL-17A blockade in recipient mice did not impact in vivo bacterial CFUs following intratracheal inoculation of free K. pneumoniae bacteria (free Kp; Figures S7A and S7C), indicating that IL-17A enhances IM-mediated bacterial inhibition. Our results indicate that IL-17A-mediated signaling in IMs enhances uptake of K. pneumoniae, potentially by increasing phagocytosis, and facilitates bacterial killing. In order to investigate the IL-17-mediated bactericidal mechanism of IMs, we developed an in vitro bacterial killing assay by co-incubating purified IMs and K. pneumoniae. Reduction of CFUs was observed in the presence of IMs, suggesting the capability of IMs to kill the pathogen in vitro ( Figure 7D ). Importantly, addition of IL-17 to the system further reduced CFUs and increased production of reactive oxygen species (ROS) by IMs ( Figure 7E ). These results suggest that IL-17 directly enhances the microbicidal activity of IMs by potentiating ROS production. In addition, TNF upregulation in response to K. pneumoniae infection was reduced in IL-17A À/À compared to WT animals ( Figure 7F ), indicating that IL-17, in addition to reinforcing the bactericidal activity of IMs, also contributes to enhanced TNF production by IMs. Addition of TNF to IM-K. pneumoniae co-cultures did not reduce CFUs ( Figure S7C ), suggesting that, unlike IL-17, TNF does not directly enhance the bactericidal capability of IMs. This is consistent with the TNFR1 À/À /CCR2-DTR bone marrow chimera experiments showing that the TNF-responsive cells are not CCR2 + ( Figure S3C ).
DISCUSSION
While TNF stands as one of the most impactful cytokines in defense against a wide range of infections, it also plays a central role in the pathogenesis of an array of inflammatory diseases. Indeed, TNF blockade represents one of the most effective treatments for autoimmune diseases, such as rheumatoid arthritis, while increasing the risk of some infectious diseases. Despite extensive investigation for over four decades, the mechanism by which TNF provides resistance against infection remains unclear and has been attributed to many effects, such as enhancing expression of chemokines, cytokines, adhesion molecules, bactericidal factors, inflammatory cell trafficking, and activating phagocyte oxidase (Sedgwick et al., 2000; Strieter et al., 2002) . The breadth of TNF's effects during infection has made it difficult to identify the key cellular and molecular pathways that facilitate pathogen inactivation and clearance. Herein, we demonstrate that during pulmonary infection with K. pneumonia, recruitment of IL17-producing ILCs to the infected lung depends on TNF production by recruited CCR2 + IMs.
TNF activates a variety of effector cells by binding to TNFR1 and promoting inflammatory responses. Although previous studies demonstrated that TNF-deficient animals are more susceptible to infection with a rodent-adapted strain of K. pneumoniae (Laichalk et al., 1996) , the TNF-producing cells in the lung and the induced effector functions have remained unclear. Our study identified monocytes as the principal TNF pro- ducers and recruitment and activation of IL-17-producing ILCs as the major downstream impact of TNF expression. Our results suggest that TNF enhances ILC recruitment to the lung by upregulating the chemokine CCL20, which has been shown to be expressed by pulmonary epithelial cells, and its expression can be boosted by TNF and IL-17 (Conti et al., 2009; Hirota et al., 2007; Kao et al., 2005; Starner et al., 2003; Sugita et al., 2002) . A recent paper described the major ILC subsets in the intestine and ILC2s in the lung as tissue-resident cells that maintain the population through self-renewal. ILC3s were not detected in the lungs during steady state or after helminth infection (Gasteiger et al., 2015) . Our work identifies the ILC3 population in the lung after acute bacterial infection and characterizes their important roles as the innate source of IL-17. Since the intestine harbors a large number of self-renewing ILC3s, whereas the lung has almost undetectable numbers of ILC3s under homeostatic conditions, we speculate that ILC3s can potentially be recruited to the infected pulmonary mucosa in a CCR6-CCL20-dependent manner from other sites. How ILC3s are recruited will require further studies.
ILCs play a crucial role in defense against a wide range of infections at mucosal sites. ILC3s that produce IL-17 and IL-22, in particular, have drawn attention in recent years due to their important role in intestinal homeostasis and disease pathogenesis. In contrast to many innate immune cells, ILCs depend on other cells to respond to infection for recruitment and activation. Indeed, it has been shown that in the intestine,
CD103
neg CD11B + DCs produce TNF, thereby enhancing IL-17 production by ILCs (Powell et al., 2012) , and CX3CR1+ mononuclear phagocytes (MNPs), which develop from CCR2 + monocyte progenitors, produce IL-1b and TL1A to stimulate or enhance ILC secretion of GM-CSF and IL-22, respectively (Longman et al., 2014; Mortha et al., 2014; Seo et al., 2015) . GM-CSF, in return, promotes MNP effector functions (Mortha et al., 2014) . The situations in the lung have been less well characterized: although Th17 cells have been demonstrated as the major protective IL-17-producing cell type in the memory response against K. pneumoniae (Chen et al., 2011) , the cell types that generate IL-17 in the primary response remain unclear. Furthermore, ILC3s in the respiratory system were not identified until recently (Kim et al., 2014) . Our findings indicate that, in the pulmonary infections, there is a similar innate source of IL-17 produced by ILC3s and, importantly, there is a similar crosstalk and feedback loop between inflammatory monocytes and ILC3s that modulate the functions of ILCs and, in return, enhance the activity of the monocytes.
Kp-MH258 belongs to the sequence type 258 (ST258), which as the dominant strain prevailing in the United States that is carbapenem resistant, has likely undergone clonal expansion and has been disseminated to other countries (García-Ferná ndez et al., 2012; Kitchel et al., 2009) . The clearance of Kp-MH258 requires inflammatory monocytes, but not neutrophils, whereas the clearance of other antibiotic-resistant, but carbapenem-sensitive, clinical isolates of K. pneumoniae requires both IMs and neutrophils . Our results indicate K. pneumoniae strains differ in their sensitivity to innate immune defenses mediated by monocytes and neutrophils. Although strains of K. pneumoniae share the same genus and species names, genetic analysis indicate substantial diversity that extends beyond antibiotic sensitivity and capsule types. Given our findings, it is likely that some of the genetic diversity between strains extends to the defense mechanism that tangles with neutrophil versus monocyte-mediated bactericidal mechanisms. Future studies will likely correlate specific genetic loci within K. pneumoniae that lead to resistance against neutrophil-mediated killing. IL-17A can bind to the IL-17RA/RC heterodimeric receptor complex (Hu et al., 2011; Kuestner et al., 2007) , which is expressed on many cell types (Kolls and Lindé n, 2004; Yao et al., 1995) . While one of the major functions of IL-17 is to facilitate neutrophil recruitment (Kolls and Lindé n, 2004; Ye et al., 2001) , its impact on IM recruitment and activation has been less clear. Previous studies demonstrated IL-17R expression on mouse and human monocytes and that IL-17 signaling can regulate their differentiation and migration Shahrara et al., 2009) . We found high IL-17R expression by lung IMs and demonstrate that IL-17 signaling enhances bacterial phagocytosis and killing by IMs. This finding provides new insights into the functional plasticity of inflammatory monocytes as both modulator and effector cells. Among the cytokines produced by RORgt-expressing ILCs, IL-22 has been implicated in the defense against the rodent-adapted K. pneumoniae strain and Streptococcus pneumoniae and is suggested to be produced by NK cells and ILC3s (Van Maele et al., 2014; Xu et al., 2014) . In contrast to these studies, clearance of the antibiotic-resistant clinical K. pneumoniae strain did not depend on IL-22 production. Given the differences in the mechanisms of cellular clearance of distinct K. pneumoniae strains, it is likely that the cytokines essential for optimal bacterial clearance will also differ.
K. pneumoniae has received much attention for its high-level antibiotic resistance, but it is also notable for the wide range of infections it can cause. In recent years, specific strains of K. pneumoniae have been discovered to cause systemic infection with liver abscess formation (Chuang et al., 2006; Fung et al., 2002) . While K. pneumoniae also causes infections of the urinary tract, bloodstream, and lungs, the associations between specific strains and infections in distinct anatomic sites are incompletely defined. Ultimately, correlating K. pneumoniae genotypes with the type of innate immune clearance mechanisms in different anatomic sites will identify factors that contribute to pathogenesis and approaches to enhance resistance that bypass the need for additional antibiotic therapy.
EXPERIMENTAL PROCEDURES
Mice C57BL/6 wild-type (WT), IL17-GFP, Rag2
, and Rag2/common gamma chain double-knockout (Rag2/cgc À/À ) mice were purchased from the Jackson Laboratory. The generation of CCR2-DTR and CCR2-GFP mice were previously described (Hohl et al., 2009) . For depletion experiments, CCR2-DTR mice were injected intraperitoneally (i.p.) with 25 ng/g body weight diphtheria toxin (DT) every other day starting 5 days before infection. The administration of aLy6G or aGr1 to WT animals were previously described . All mice were bred and maintained under specific pathogen-free conditions at the Memorial Sloan Kettering Research Animal Resource Center. Sex-, age-, and weight-matched controls were used in all experiments according to institutional guidelines for animal care. All animal procedures were approved by the Institutional Animal Care and Use Committee of the Memorial Sloan-Kettering Cancer Center. Endpoints were met when animals were moribund or lost a significant percentage (>20%) of body weight.
For antibody-mediated depletion, antibodies were purchased from BioXCell. In order to achieve a complete depletion in the lung, anti-IL-17A antibody (clone: 17F3; catalog #: BE0173) was administered to mice through i.p. injection (400 mg), intravenous (i.v.) injection (200 mg), and intratracheal instillation (200 mg) on a daily base starting 1 day before infection. Anti-CD90 antibody (clone: T24/31; catalog #: BE0212) was delivered through i.p. injection (250 mg), i.v. injection (100 mg), and intratracheal instillation (100 mg) on day À4, À2, 0, 2, and 4 of infection. Anti-TNF antibody (clone: TN3-19.12; catalog #: BE0091) was administered through i.p. injection (400 mg) and intratracheal instillation (100 mg) on a daily base starting from day À1 of infection.
Regarding the bone marrow chimera, recipient animals received 1,000 r whole-body lethal irradiation and were grafted with 5 3 10 6 T cell-depleted bone marrow cells on the next day. Mice were maintained on antibiotic water for 2 weeks after engraftment.
Bacterial Strains
Clinical K. pneumoniae isolate Kp-MH258 that belongs to sequencing type 258 (ST258) was used in this study. The bacteria were grown in LB media to log phase. Optical density 600 was measured, and the cultures were diluted accordingly in PBS to 1 3 10 4 CFU/ ml for intratracheal instillation.
Intratracheal Instillation
Animals were anesthetized by ketamine through i.p. injection. 40 ml of bacterial inoculum, IM suspension, or antibody was applied to the trachea through the mouth via a curved, blunt-end needle. Mice were held vertically for 1 min after the inoculation.
Tissue Homogenization
The whole lung was perfused before harvest, homogenized, and digested with 5% fetal calf serum, 5,000 U/ml collagenase type IV (Worthington), and 20 U/ml DNase (Roche) and was incubated at 37 C for 40 min to obtain single-cell suspension for staining or plating.
Flow Cytometry
Single-cell suspensions were stained and analyzed on a BD LSR II cytometer. Antibodies were purchased from BD Bioscience unless otherwise listed. For monocyte, neutrophil, DC, macrophage, and T cell stainings, the following antibodies were used: anti-Ly6C (clone AL-21), Ly6G (1A8), CD11b (M1/70), CD45 (30F-11), CD11c (HL3), CD103 (2E7), NK1.1(PK136), CD49b(PanNK)(DX5), CD3 (145-2C11), CD4 (L3T4), gd TCR (GL3), TNF (MP6-XT22), and IL-17RA (PAJ-17R). For ILC staining, the following antibodies were used: Lineage 1(Lin1, in FITC): CD3, CD4, CD8 (53-6.7), and CD11c; Lineage2 (Lin2, in PE-CY7): CD11b, NK1.1, CD19 (1D3), Ter119 and (TER119). CD45, CD45.1 (A20), CD45.2 (104), CD90 (53-2.1), and CD127 (A7R34) were used for subsequent positive gating.
For intracellular TNF staining, a BD Cytofix/Cytoperm Plus Kit (with BD GolgiPlug) (cat# 555028) with protein transport inhibitor (containing Brefeldin A) (cat#555029) was used. Brefeldin A was added in the digestion and staining buffers. For intracellular IL-17A and IL-22 staining, the antibodies were purchased from eBioscience (clone: eBio17B7, cat# 17-7177-81 for anti-IL-17; clone: IL22JOP, cat# 17-7222-82 for anti-IL-22). Intracellular Fixation & Permeabilization Buffer (plus Brefeldin A) (cat# 88-8823-88) was used. Cells were stimulated in vitro with ionomycin (750 ng/ml), PMA (50 ng/ml), and IL-23 (40 ng/ml) for 3 hr before IL-17A/IL-22 staining.
BrdU Staining
A BrdU Flow Kit from BD (#559619) was used. In brief, 2.5 mg BrdU solution was injected i.p. into mice 30 min before infection. Animals were sacrificed on day 1, following infection, and cells were permeabilized, fixed, and stained according to the kit's protocol.
MACs Beads Sorting
An anti-Ly6G Microbead Kit (130-092-332) and anti-CD11b beads (130-049-601) were purchased from Miltenyi Biotec. A LS column was used for the purification of the bead-bound cells. First, an anti-Ly6G kit was used to pull down neutrophils, and then anti-CD11b beads were applied to the Ly6G -fraction to purify IMs. Isolated cells were stained and analyzed using flow cytometry to check the purity.
Adoptive Inflammatory Monocyte Transfer
Inflammatory monocytes were harvested from the bone marrow of CCR2-GFP mice. The cells were stained with PE antibodies as shown in Figure S2A . PE À GFP + cells were sorted by the Memorial Sloan-Kettering Cancer Center flow cytometry core facility. The cells were resuspended in PBS and injected intravenously to the recipient mice. This strategy did not require antibody staining for trafficking molecules (CCR2 and CD11b) and eliminated NK cells, T cells, dendritic cell progenitors, and hematopoietic stem cells, yielding a highly purified (>99%) population of IMs. Bacterial Killing Assay IMs were purified from the bone marrow of CCR2-GFP mice as Figure S2 shows. 1 3 10 5 IMs were mixed with 100 CFUs of K. pneumoniae using antibiotic-free cRPMI medium in a 96-well plate. PBS or 100 ng/ml recombinant IL-17 (rmIL-17) was added to the culture. The plate was briefly centrifuged and incubated at 37 C, and supernatant was collected and plated at the designated time points for bacterial counts. A CellROX Staining Kit (Invitrogen) was added to the culture to measure the production of ROS by IMs.
Real-Time PCR Cells were collected in Trizol. Chloroform and 2-propanol were used to extract and precipitate RNA, respectively. Reverse transcription was performed using QuantiTect Reverse Transcription Kit (QIAGEN). Primers were ordered from the Taqman Web site. The real-time PCR reaction was run with the Thermo Scientific DyNAmo Flash Probe qPCR Kit for the amplification and quantification of cDNA. The expression level was normalized to that of b-actin.
Statistical Analysis
All data were analyzed using GraphPad Prism software and are presented as the arithmetic mean ± SEM. Statistical validation was done with the Student's t test. *p < 0.05, **p < 0.01, ***p < 0.001. p < 0.05 is considered statistically significant.
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